Prior to the restructuring,
For further information about
Jeppe Øvlesen
CEO, SynAct Pharma AB CSO,
Phone: +45 28 44 75 67 Phone: +45 40 15 66 69
Mail: joo@synactpharma.com Mail: tj@synactpharma.com
This information was submitted, through the agency of the contact persons set out above, for publication on
About
About AP1189
The mechanism of action of SynAct Pharma's lead compound AP1189 is to promote resolution of inflammation through melanocortin receptor activation directly on macrophages, thereby reducing the pro-inflammatory activity of macrophages and by stimulating so-called macrophage efferocytosis, a specific ability to clear inflammatory cells (J Immun 2015, 194:3381-3388). This effect has shown to be effective in disease models of inflammatory and autoimmune diseases and the clinical potential of the approach is currently tested in a clinical phase 2 study in patient with active rheumatoid Arthritis, in nephrotic syndrome and COVID-19 inflammation ARDS. https://clinicaltrials.gov/ct2/show/NCT04004429?term=AP1189&draw=2&rank=1)
https://clinicaltrials.gov/ct2/show/NCT04456816?term=AP1189&draw=2&rank=2
https://news.cision.com/synact/r/published-in-english---already-published-11-18-cet-today-disclosure-notice-in-synact-pharma-ab,c3266100
https://mb.cision.com/Main/14427/3266100/1357777.pdf
(c) 2021 Cision. All rights reserved., source